Antibe Therapeutics Inc.’s Founder and Chief Scientific Officer, Dr.
John Wallace, is the senior author of an article published this week in
the prestigious scientific journal Proceedings of the National
Academy of Science USA describing research that may lead to a
significant improvement in the treatment of Crohn’s Disease and
Ulcerative Colitis, collectively known as “inflammatory bowel disease”
(IBD).
IBD affects almost 200,000 Canadians, and many millions of others
worldwide. The incidence of IBD is increasing, particularly in young
children. There is no cure for IBD, and treatment options are limited
and often inadequate.
Dr. Wallace’s research group demonstrated a key role of hydrogen sulfide
in promoting repair of intestinal injury. Using mice having a genetic
defect similar to that found in many IBD patients, the research
demonstrated that small amounts of hydrogen sulfide-releasing agents
could rapidly reduce the intestinal inflammation and ulceration that
developed in these mice.
Dr. Wallace commented: “We are excited by the results of this study and
very grateful to Crohn’s Colitis Canada and the Canadian Institutes of
Health Research for funding this research”.
The article can be accessed via the following link:
http://www.antibethera.com/Articles/PNAS_2014
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright Business Wire 2014